Detalhe da pesquisa
1.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood
; 143(20): 2029-2036, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394666
2.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
3.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
4.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
5.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
6.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654611
7.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol
; 20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197267
8.
Hairy cell leukaemia with unusual BRAF mutations.
J Cell Mol Med
; 27(17): 2626-2630, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37530550
9.
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Br J Haematol
; 201(6): 1103-1115, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974007
10.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
11.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031755
12.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica
; 108(10): 2774-2782, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078253
13.
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
Am J Hematol
; 98(2): 264-271, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588407
14.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
15.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
16.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood
; 135(18): 1531-1540, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108228
17.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
18.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
19.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
20.
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
N Engl J Med
; 376(14): 1311-1320, 2017 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28379796